{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:42:08Z","timestamp":1793256128432,"version":"4.5.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:sec id=\"ab-dbr250002-4\"><jats:title>Importance<\/jats:title><jats:p>Currently available biologics specifically target dermal adaptive immune molecules, such as interleukin (IL)-17 and IL-23, which are crucial in the pathogenesis of psoriasis. Despite their remarkably enhanced therapeutic effects compared with those of traditional anti-inflammatory systemic medications, 25% to 50% of patients are still resistant to biologic therapy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr250002-5\"><jats:title>Objective<\/jats:title><jats:p>To delineate the inflammatory microenvironmental factors that affect sustained treatment response in patients with severe psoriasis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr250002-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>A cross-sectional study was carried out including patients aged 18 years or older who visited the Gachon University Gil Medical Center dermatology clinic between January 2012 and December 2022 with plaque-type severe psoriasis with a Psoriasis Area and Severity Index score greater than 10 and body surface area larger than 10 despite conventional treatment with cyclosporine, methotrexate, acitretin, and phototherapy for longer than 3 months, and treatment with biologics for at least 24 months. Analysis was carried out from December 2023 to September 2024.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr250002-7\"><jats:title>Main Outcome and Measure<\/jats:title><jats:p>Clinical and inflammatory factors associated with sustained response to biologics therapy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr250002-8\"><jats:title>Results<\/jats:title><jats:p>Among the 87 patients (mean [SD] age, 42.2 [12.5] years; 24 female patients and 63 male patients) included in the study, 16 (18.4%) had to switch to other biologics because of an early loss of therapeutic efficacy. Having overweight (body mass index, &amp;amp;gt;25) was the only clinically relevant factor (odds ratio, 17.3; 95% CI, 3.2-434.6; <jats:italic>P<\/jats:italic>\u2009=\u2009.009). Other factors, including initial disease severity before biologics or disease duration until the first use of biologics, were not different between patients with treatment-resistant disease and those with a sustained treatment response. Spatial transcriptomics pathway analyses revealed enriched innate immune signaling and T-helper 17 cells (Th17)\/IL-17 signaling pathways, with upregulated expression of innate immune- or neutrophil-related genes, such as <jats:italic>TNFSF10<\/jats:italic>, <jats:italic>CXCL8<\/jats:italic>, <jats:italic>LCN2<\/jats:italic>, <jats:italic>S100A8<\/jats:italic>, and <jats:italic>S100A9<\/jats:italic>, mainly in the epidermis. Enriched ligand-receptor interactions were observed in the IL-36 family of cytokines, antimicrobial peptides, and tumor necrosis factor (TNF) signaling. Immunofluorescence analysis showed enhanced protein expression of lipocalin 2, S100A8\/A9, IL-36\u03b1, IL-36\u03b3, IL-1RA, and TNF-related apoptosis-inducing ligand (TRAIL) in the epidermis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr250002-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This cross-sectional study found that dysregulated innate immune responses in the epidermis and heightened neutrophil activity may be responsible for decreased sustainability of therapeutic responses to biologics. Given that current biologics mainly target dermal adaptive immune-related mediators, the development of novel therapeutic strategies to target the epidermal innate immune response, including neutrophils, is warranted.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.0288","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T16:36:37Z","timestamp":1743784597000},"page":"629","source":"Crossref","is-referenced-by-count":20,"title":["Association of Obesity and Innate Immune Markers With Resistance to Biologic Therapy in Psoriasis"],"prefix":"10.1001","volume":"161","author":[{"given":"Hee Joo","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Dermatology, Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea"},{"name":"Lee Gil Ya Cancer and Diabetes Institute, Gachon University College of Medicine, Incheon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Hui","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Gachon University College of Medicine, Incheon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YunJae","family":"Jung","sequence":"additional","affiliation":[{"name":"Lee Gil Ya Cancer and Diabetes Institute, Gachon University College of Medicine, Incheon, South Korea"},{"name":"Department of Microbiology, Gachon University College of Medicine, Incheon, South Korea"},{"name":"Department of Health Science and Technology, Gachon Advanced Institute for Health Science & Technology, Gachon University, Incheon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"dbr250002r1","doi-asserted-by":"publisher","first-page":"928","DOI":"10.25259\/IJDVL_308_2022","article-title":"Review of the reasons for and effectiveness of switching biologics for psoriasis treatment in Korea.","volume":"89","author":"Shin","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"5","key":"dbr250002r2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","article-title":"Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French Health Insurance Database.","volume":"158","author":"Pina Vegas","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"6","key":"dbr250002r3","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3390\/jcm11061506","article-title":"Adherence and persistence to biological drugs for psoriasis: systematic review with meta-analysis.","volume":"11","author":"Piragine","year":"2022","journal-title":"J Clin Med"},{"issue":"7","key":"dbr250002r4","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/jdv.12208","article-title":"Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry.","volume":"28","author":"Carrascosa","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"dbr250002r5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bjd.14552","article-title":"Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.","volume":"175","author":"Zweegers","year":"2016","journal-title":"Br J Dermatol"},{"issue":"4","key":"dbr250002r6","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.4049\/jimmunol.1003162","article-title":"IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression.","volume":"186","author":"Johnston","year":"2011","journal-title":"J Immunol"},{"issue":"12","key":"dbr250002r7","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1038\/jid.2011.234","article-title":"Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis.","volume":"131","author":"Carrier","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"1","key":"dbr250002r8","first-page":"17","article-title":"Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL): a possible pathogenic role in chronic plaque psoriasis.","volume":"151","author":"Caldarola","year":"2016","journal-title":"G Ital Dermatol Venereol"},{"issue":"11","key":"dbr250002r9","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/j.1600-0625.2012.01571.x","article-title":"Novel insights into the role of S100A8\/A9 in skin biology.","volume":"21","author":"Kerkhoff","year":"2012","journal-title":"Exp Dermatol"},{"issue":"6","key":"dbr250002r10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.clindermatol.2007.08.016","article-title":"Innate immunity and antimicrobial defense systems in psoriasis.","volume":"25","author":"B\u00fcchau","year":"2007","journal-title":"Clin Dermatol"},{"issue":"3","key":"dbr250002r11","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","article-title":"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.","volume":"144","author":"Krueger","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"dbr250002r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.155828","article-title":"Interleukin-8: an evolving chemokine.","volume":"153","author":"Matsushima","year":"2022","journal-title":"Cytokine"},{"issue":"8","key":"dbr250002r13","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/j.jid.2021.01.019","article-title":"IL-36 and IL-17A cooperatively induce a psoriasis-like gene expression response in human keratinocytes.","volume":"141","author":"Miura","year":"2021","journal-title":"J Invest Dermatol"},{"key":"dbr250002r14","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.2147\/JIR.S358492","article-title":"Lipocalin 2 participates in the epidermal differentiation and inflammatory processes of psoriasis.","volume":"15","author":"Ren","year":"2022","journal-title":"J Inflamm Res"},{"issue":"2","key":"dbr250002r15","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/sj.jid.5700035","article-title":"Expression of neutrophil gelatinase-associated lipocalin in skin epidermis.","volume":"126","author":"Seo","year":"2006","journal-title":"J Invest Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2832061\/jamadermatology_kim_2025_br_250002_1748911548.32744.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T15:01:24Z","timestamp":1750258884000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2832061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.0288","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}